Numerous Phase I through Phase IV clinical trials evaluate the therapeutic efficacy and safety of dapagliflozin across diverse indications, including type 2 diabetes, heart failure, chronic kidney disease, peritoneal dialysis complications, and solid tumors. Ranging in recruitment status from not yet recruiting to completed, these studies are sponsored by pharmaceutical industry leaders such as AstraZeneca alongside global academic medical centers and university hospital networks.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06364930 | RECRUITING | Chronic Hepatitis B |
Chinese University of Hong Kong |
2024-03-26 | PHASE4 |
| NCT07280585 | RECRUITING | Polycystic Kidney, Autosomal Dominant |
University of Cologne |
2025-12-16 | PHASE3 |
| NCT06742723 | RECRUITING | Chronic Kidney Disease and Hypertension |
AstraZeneca |
2025-03-03 | PHASE3 |
| NCT06677060 | RECRUITING | Heart Failure |
AstraZeneca |
2025-03-14 | PHASE3 |
| NCT07310433 | NOT_YET_RECRUITING | Prostate Cancer; Metastatic Prostate Cancer |
Yung NA |
2026-06-01 | PHASE2 |
| NCT06642623 | RECRUITING | Diabetes Mellitus, Type 2; Cardiovascular Diseases; Kidney Diseases |
Yonsei University |
2024-01-22 | PHASE4 |
| NCT07539259 | NOT_YET_RECRUITING | Aortic Stenosis |
University College, London |
2026-12 | PHASE2 |
| NCT07323524 | RECRUITING | Lupus Nephritis (LN) |
Brigham and Women's Hospital |
2026-05-19 | PHASE4 |
| NCT07729592 | NOT_YET_RECRUITING | Hepatocellular Carcinoma (HCC) |
Sun Yat-sen University |
2026-07 | PHASE2 |
| NCT07025629 | RECRUITING | Heart Failure and Chronic Kidney Disease Post-ICU |
Assistance Publique - Hôpitaux de Paris |
2025-12-02 | PHASE3 |
| NCT06642272 | RECRUITING | Diabetes Mellitus, Type 2; Heart Failure; Chronic Kidney Diseases |
Herlev and Gentofte Hospital |
2024-10-10 | PHASE4 |
| NCT07741890 | NOT_YET_RECRUITING | Angina With Non-Obstructive Coronary Artery Disease; Coronary Microvascular Dysfunction (CMD) |
The Christ Hospital |
2026-09-01 | PHASE2 |
| NCT07342764 | NOT_YET_RECRUITING | Antipsychotic-induced Weight Gain (AIWG); Antipsychotic-induced Weight Gain |
Sultan Qaboos University |
2026-09 | PHASE4 |
| NCT07245069 | RECRUITING | Heart Failure; Anthracycline-induced Cardiac Toxicity; Endothelial Function (FMD); Arterial Stiffness; Breast Cancer |
University Medical Centre Ljubljana |
2025-02-01 | PHASE2 |
| NCT06140537 | RECRUITING | Kidney Transplant; Complications; Vascular Diseases; Diabetes |
University of Colorado, Denver |
2024-02-01 | PHASE4 |
| NCT05321706 | ACTIVE_NOT_RECRUITING | Heart Transplant Failure; Kidney Failure |
Oslo University Hospital |
2022-06-08 | PHASE3 |
| NCT07273838 | RECRUITING | Heart Failure; Acute Kidney Injury |
Yale University |
2026-03-05 | PHASE2 |
| NCT07491718 | RECRUITING | Takotsubo Cardiomyopathy |
University of Edinburgh |
2025-08-08 | |
| NCT06785116 | RECRUITING | Gestational Hypertension; Hypertension in Pregnancy; Pre-Eclampsia; Superimposed Pre-Eclampsia; Cardiovascular Complication |
University of Michigan |
2025-03-02 | PHASE4 |
| NCT04591639 | RECRUITING | Heart Failure; Diabetic Cardiomyopathies |
University of Edinburgh |
2020-08-19 | |
| NCT07662044 | RECRUITING | Type 2 Diabetes Mellitus |
AstraZeneca |
2026-07-06 | PHASE3 |
| NCT07662135 | RECRUITING | Type 2 Diabetes Mellitus; Type 2 Diabetes With Chronic Kidney Disease |
AstraZeneca |
2026-07-06 | PHASE3 |
| NCT07662109 | RECRUITING | Type 2 Diabetes Mellitus |
AstraZeneca |
2026-07-06 | PHASE3 |
| NCT06907251 | NOT_YET_RECRUITING | COVID - 19; Long COVID Syndrome; SARS CoV-2 |
Ottawa Heart Institute Research Corporation |
2026-09-01 | PHASE3 |
| NCT07235280 | RECRUITING | Lung Adenocarcinoma; Stage IA1 Lung Cancer American Joint Committee on Cancer (AJCC) v8; Stage IA2 Lung Cancer AJCC v8; Stage IA3 Lung Cancer AJCC v8; Lung Cancer |
Jonsson Comprehensive Cancer Center |
2025-12-02 | EARLY_PHASE1 |
| NCT05788276 | RECRUITING | Kidney Transplant; Complications; Kidney Transplant Failure; Renal Failure |
Oslo University Hospital |
2023-05-02 | PHASE4 |
| NCT07239570 | RECRUITING | Chronic Kidney Disease(CKD) |
Peter Rossing |
2025-06-20 | PHASE4 |
| NCT06268873 | ACTIVE_NOT_RECRUITING | Chronic Kidney Disease and Hypertension |
AstraZeneca |
2024-03-29 | PHASE3 |
| NCT07225465 | NOT_YET_RECRUITING | Type 1 Diabetes Mellitus |
St Vincent's Hospital Melbourne |
2026-02 | PHASE2 |
| NCT07469722 | NOT_YET_RECRUITING | Acute Heart Failure (AHF); Congestive Heart Failure Acute; Diuretic Effect; Lung Ultrasonography Score; Ultrasonography, Doppler; Point-of-care Ultrasound (POCUS) |
Hospital de Clinicas de Porto Alegre |
2026-03-23 | PHASE2; PHASE3 |
| NCT06562582 | RECRUITING | Myocardial Infarct |
Vastra Gotaland Region |
2025-01-06 | PHASE4 |
| NCT05852704 | RECRUITING | Chronic Coronary Syndrome; Atrial Fibrillation |
Region Örebro County |
2024-04-04 | PHASE3 |
| NCT05989347 | RECRUITING | Breast Cancer; Hyperinsulinism; HER2-negative Breast Cancer |
Yale University |
2024-10-15 | PHASE1 |
| NCT07392788 | NOT_YET_RECRUITING | Acute Heart Failure (AHF) |
Centre Hospitalier Universitaire de Besancon |
2026-04 | |
| NCT07174687 | RECRUITING | Retinal Degeneration; Retinal Diseases; Eye Diseases; Geographic Atrophy; Pathological Conditions, Anatomical |
Washington University School of Medicine |
2025-12-02 | PHASE2 |
| NCT07403955 | NOT_YET_RECRUITING | Congestive Heart Failure Acute |
Qilu Hospital of Shandong University |
2026-02 | |
| NCT07187570 | RECRUITING | Atrial Fibrillation (AF) |
Region Stockholm |
2025-06-03 | PHASE3 |
| NCT07436663 | NOT_YET_RECRUITING | Breast Cancer |
Tanta University |
2026-02-01 | PHASE4 |
| NCT07096986 | NOT_YET_RECRUITING | Glomerulonephritis |
Centre Hospitalier Universitaire de Nice |
2026-11-01 | PHASE2 |
| NCT07778719 | NOT_YET_RECRUITING | Type 2 Diabetes; Metabolic Dysfunction-Associated Steatotic Liver Disease |
The 95th Hospital of Putian，Putian, Fujian, China |
2026-10-01 | |
| NCT05938712 | RECRUITING | Kidney Transplant Recipients |
University Health Network, Toronto |
2023-10-24 | PHASE2 |
| NCT07147114 | RECRUITING | Combined Pre- and Post-capillary Pulmonary Hypertension; CpcPH; HFmrEF; HFpEF; Group 2 Pulmonary Hypertension |
Gachon University Gil Medical Center |
2025-11-24 | PHASE4 |
| NCT07776054 | RECRUITING | Atrial Fibrillation; SGLT2 Inhibitor; DC Cardioversion |
Samsung Medical Center |
2024-02-01 | PHASE4 |
| NCT06887062 | RECRUITING | Large Vessel Vasculitis; Giant Cell Arteritis (GCA); Takayasu Arteritis |
University of Edinburgh |
2025-03-21 | PHASE2 |
| NCT05374291 | ENROLLING_BY_INVITATION | Kidney Disease, Chronic; Renal Transplant Failure; Heart Failure; Kidney Failure; Death |
University Medical Center Groningen |
2022-11-08 | PHASE3 |
| NCT06528405 | RECRUITING | Acute Kidney Injury |
National Taiwan University Hospital |
2024-11-21 | PHASE2 |
| NCT06307652 | RECRUITING | Heart Failure and Impaired Kidney Function |
AstraZeneca |
2024-04-12 | PHASE3 |
| NCT07614230 | RECRUITING | Type 2 Diabetes Mellitus (T2DM); Coronary Artery Disease; Atherosclerosis |
Junjie Yang |
2026-01-01 | PHASE4 |
| NCT07405216 | RECRUITING | Chronic Kidney Disease (Mild to Moderate); Albuminuria; Adolescent; Sodium Glucose Co-Transporter 2 Inhibitors |
Centenario Hospital Miguel Hidalgo |
2026-04-23 | PHASE4 |
| NCT07598864 | NOT_YET_RECRUITING | Diabetic Nephropathy |
Chittagong Medical College |
2026-05-01 | PHASE3 |
| NCT06420167 | RECRUITING | Renal AL Amyloidosis |
Barbara Ann Karmanos Cancer Institute |
2024-07-11 | PHASE2 |
| NCT05174052 | RECRUITING | Diabetes Mellitus; Atrial Fibrillation |
University of Oklahoma |
2022-06-01 | PHASE3 |
| NCT06868797 | RECRUITING | Heart Failure |
Central Hospital, Nancy, France |
2025-08-29 | |
| NCT07297589 | RECRUITING | STEMI - ST Elevation Myocardial Infarction; Epicardial Fat |
Instituto Mexicano del Seguro Social |
2025-12-30 | PHASE3 |
| NCT06668389 | RECRUITING | Congenital Heart Disease; Repaired Tetralogy of Fallot (rTOF); Pulmonary Regurgitation; Sodium-glucose Cotransporter 2 (SGLT2) Inhibitor; Dapagliflozin (Forxiga) |
The University of Hong Kong |
2025-05-12 | PHASE4 |
| NCT06890143 | RECRUITING | Pediatric Hereditary Kidney Diseases |
Children's Hospital of Fudan University |
2025-03-22 | PHASE3 |
| NCT07595289 | NOT_YET_RECRUITING | Type 2 Diabetes Mellitus (T2DM) |
The Third Xiangya Hospital of Central South University |
2026-08-01 | |
| NCT06155604 | RECRUITING | Lupus Nephritis; Chronic Kidney Diseases |
The University of Hong Kong |
2023-01-04 | PHASE2 |
| NCT06759909 | NOT_YET_RECRUITING | Dapagliflozin (Forxiga); Atrial Fibrillation (AF) |
Assiut University |
2025-01-03 | PHASE1 |
| NCT07222917 | ACTIVE_NOT_RECRUITING | Chronic Kidney Disease and Hypertension |
AstraZeneca |
2025-12-05 | PHASE2 |
| NCT02969798 | RECRUITING | Diabetes Mellitus, Type 2; Impaired Glucose Tolerance (IGT); Impaired Fasting Glucose (IFG) |
The University of Texas Health Science Center at San Antonio |
2014-01-01 | |
| NCT06111443 | ACTIVE_NOT_RECRUITING | Atrial Fibrillation Recurrent; Catheter Ablation |
Chang Gung Memorial Hospital |
2023-12-01 | PHASE2; PHASE3 |
| NCT07239011 | RECRUITING | Depression |
Tanta University |
2025-11-01 | PHASE1; PHASE2 |
| NCT06772168 | RECRUITING | Dyslipidemia; Type 2 Diabetes |
CMG Pharmaceutical Co. Ltd |
2024-04-19 | PHASE3 |
| NCT06560801 | RECRUITING | Chronic Kidney Diseases |
University of Erlangen-Nürnberg Medical School |
2023-07-28 | PHASE4 |
| NCT07351643 | NOT_YET_RECRUITING | ACS (Acute Coronary Syndrome); SGLT2 Inhibitors |
Shenyang Northern Hospital |
2026-02-25 | PHASE4 |
| NCT06750458 | NOT_YET_RECRUITING | Glioma; Dapagliflozin (Forxiga); Dexamethasone |
Tanta University |
2025-08-20 | PHASE3 |
| NCT05764057 | RECRUITING | AMI; STEMI; NSTEMI; Left Ventricular Dysfunction |
Assistance Publique - Hôpitaux de Paris |
2023-06-12 | PHASE3 |
| NCT06972732 | RECRUITING | Type 2 Diabetes |
Boryung Pharmaceutical Co., Ltd |
2025-06-11 | PHASE4 |
| NCT06427226 | RECRUITING | Doxorubicin Induced Cardiomyopathy; Breast Cancer |
Tanta University |
2024-10-31 | PHASE2 |
| NCT07555106 | ACTIVE_NOT_RECRUITING | Kidney Transplant; Kidney Transplant Failure |
University of Guadalajara |
2024-09-15 | PHASE2 |
| NCT07331727 | NOT_YET_RECRUITING | Atrial Fibrillation (AF) |
Shanghai Chest Hospital |
2026-01-01 | |
| NCT05719714 | ACTIVE_NOT_RECRUITING | Chronic Kidney Diseases; Heart Failure With Preserved Ejection Fraction; Kidney Diseases; Heart Failure |
Northwestern University |
2024-01-16 | PHASE1; PHASE2 |
| NCT07491042 | RECRUITING | End Stage Chronic Renal Failure |
Oman Ministry of Health |
2026-04-01 | |
| NCT07018622 | RECRUITING | Solid Tumors; Cisplatin Nephrotoxicity |
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
2025-05-07 | PHASE2 |
| NCT06942910 | ACTIVE_NOT_RECRUITING | Chronic Kidney Disease With High Proteinuria |
AstraZeneca |
2025-05-07 | PHASE2 |
| NCT06922656 | NOT_YET_RECRUITING | Type 1 Diabetes |
Dasman Diabetes Institute |
2025-09-15 | PHASE4 |
| NCT05944016 | RECRUITING | Chronic Kidney Failure in Children and Young Adults |
University Hospital Goettingen |
2024-03-25 | PHASE3 |
| NCT06009874 | UNKNOWN | Myocardial Infarction |
Mohammad Hussien Tantawy Soliman |
2023-10 | |
| NCT07083401 | RECRUITING | Diabete Mellitus |
Boryung Pharmaceutical Co., Ltd |
2025-07-05 | PHASE1 |
| NCT07214818 | RECRUITING | Nephrotic Syndrome |
Mansoura University |
2025-11-15 | PHASE2; PHASE3 |
| NCT07083388 | RECRUITING | Diabetes Mellitus |
Boryung Pharmaceutical Co., Ltd |
2025-07-03 | PHASE1 |
| NCT06317051 | ACTIVE_NOT_RECRUITING | HIV Infections; Weight Gain |
Kirby Institute |
2024-12-16 | PHASE3 |
| NCT06851962 | COMPLETED | Diabetes Mellitus Type 2 |
Fundación para la Investigación del Hospital Clínico de Valencia |
2025-05-26 | PHASE4 |
| NCT05345327 | RECRUITING | Type 2 Diabetes |
The George Institute |
2023-01-01 | PHASE3 |
| NCT06398977 | RECRUITING | Peritoneal Dialysis Complication; Renal Function Aggravated; Sodium-glucose Co-transporter-2 Inhibitors |
Sichuan Academy of Medical Sciences |
2024-03-11 | |
| NCT06373523 | ACTIVE_NOT_RECRUITING | Hepatic Steato-Fibrosis; Non-Alcoholic Fatty Liver Disease |
Post Graduate Institute of Medical Education and Research, Chandigarh |
2024-01-15 | EARLY_PHASE1 |
| NCT06982079 | RECRUITING | Chronic Kidney Disease Stage 5; CKD Stage 4 |
Ain Shams University |
2025-05-01 | PHASE3 |
| NCT07204743 | ACTIVE_NOT_RECRUITING | SGLT 2 Inhibitors; Pediatric Kidney Disease; Proteinuric Diseases; Dapagliflozin (Forxiga) |
Al-Quds University |
2025-08-15 | |
| NCT07076615 | COMPLETED | Acute Decompensated Heart Failure (ADHF) |
May Mohamed Abdalla |
2025-08-01 | PHASE4 |
| NCT06589765 | COMPLETED | Type 2 Diabetes |
Shandong Suncadia Medicine Co., Ltd. |
2024-09-27 | PHASE3 |
| NCT06434025 | NOT_YET_RECRUITING | Heart Failure, Systolic; Iron Deficiencies |
Hospital de Clinicas de Porto Alegre |
2024-05-24 | PHASE3 |
| NCT06740786 | NOT_YET_RECRUITING | Atrial Fibrillation (AF) |
Xu Liu |
2024-12-10 | |
| NCT05886088 | NOT_YET_RECRUITING | Type 2 Diabetes Mellitus |
EMS |
2024-02 | PHASE3 |
| NCT07351864 | NOT_YET_RECRUITING | Heart Failure |
Mansoura University |
2026-01-18 | PHASE4 |
| NCT07610174 | COMPLETED | Heart Failure; Heart Valve Prosthesis |
Kafrelsheikh University |
2025-06-02 | PHASE2 |
| NCT07404137 | COMPLETED | Healthy Participants |
AstraZeneca |
2026-02-16 | PHASE1 |
| NCT06405178 | COMPLETED | Polycystic Ovary |
Beni-Suef University |
2026-03-30 | PHASE3 |
| NCT05741658 | COMPLETED | Heart Failure |
Johns Hopkins University |
2023-11-08 | PHASE4 |
| NCT06820567 | NOT_YET_RECRUITING | Chronic Kidney Diseases; Diabetes Type 2 |
Assiut University |
2025-03-01 | PHASE3 |
| NCT06845163 | RECRUITING | Diabetic Macular Edema; Center-involved Diabetic Macular Edema |
Alexandria University |
2025-02-08 | PHASE2 |
| NCT07399470 | COMPLETED | Healthy Volunteers; Fasting Conditions |
LG Chem |
2026-01-09 | PHASE1 |
| NCT05965440 | COMPLETED | Chronic Kidney Diseases |
Hospices Civils de Lyon |
2023-11-20 | |
| NCT06442280 | UNKNOWN | Heart Failure Acute; Diabetes Type 2; Heart Failure With Reduced Ejection Fraction; Heart Failure With Preserved Ejection Fraction |
University of Palermo |
2024-06 | PHASE4 |
| NCT03899402 | ACTIVE_NOT_RECRUITING | Type 1 Diabetes Mellitus |
State University of New York at Buffalo |
2019-05-01 | PHASE2; PHASE3 |
| NCT03982381 | COMPLETED | Type 2 Diabetes |
Uppsala University |
2019-09-05 | PHASE4 |
| NCT06711185 | RECRUITING | Breast Cancer |
University of Campinas, Brazil |
2024-01-30 | PHASE3 |
| NCT05179356 | COMPLETED | Pulmonary Arterial Hypertension; Chronic Thromboembolic Pulmonary Hypertension |
Mads Ersbøll |
2023-01-01 | PHASE2 |
| NCT06626737 | RECRUITING | Graft-versus-host Disease (GVHD) |
The First Affiliated Hospital of Soochow University |
2025-04-26 | PHASE2 |
| NCT06875193 | RECRUITING | Type2diabetes |
Dong Wha Pharmaceutical Co. Ltd. |
2024-05-28 | PHASE4 |
| NCT05884866 | COMPLETED | Chronic Renal Failure; Mechanistic Effects of SGLT2 Inhibition and/ or MR Antagonism on Body Fluid and Electrolyte Homeostatis; Chronic Kidney Disease Stage 3; Electrolyte and Fluid Balance Conditions |
Klinikum Nürnberg |
2023-07-13 | PHASE2 |
| NCT07020377 | ACTIVE_NOT_RECRUITING | Diabetes Mellitus; Non Alcholic Fatty Liver Disease |
Amira Bisher,PhD |
2024-01-15 | PHASE1; PHASE2 |
| NCT02616666 | COMPLETED | Type 2 Diabetes Mellitus |
University of Liverpool |
2016-08-25 | PHASE4 |
| NCT06578520 | RECRUITING | Heart Failure |
Fundación para la Investigación del Hospital Clínico de Valencia |
2024-07-30 | PHASE4 |
| NCT05782972 | ACTIVE_NOT_RECRUITING | Metabolic Associated Fatty Liver Disease |
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation |
2023-03-11 | PHASE4 |
| NCT07333742 | COMPLETED | Fed Conditions; Healthy Volunteer |
LG Chem |
2025-09-29 | PHASE1 |
| NCT04887935 | TERMINATED | Prostate Cancer; Cancer of Prostate |
Washington University School of Medicine |
2024-06-04 | PHASE1 |
| NCT06499948 | COMPLETED | Alport Syndrome; Thin Basement Membrane Disease; Alport Nephropathy |
Stefan Lujinschi |
2024-02-26 | PHASE4 |
| NCT06165601 | COMPLETED | Chronic Kidney Diseases |
University Hospital, Montpellier |
2024-01-04 | |
| NCT06491680 | RECRUITING | Breast Cancer |
Helwan University |
2024-09-10 | PHASE4 |
| NCT06897605 | RECRUITING | Chronic Kidney Disease(CKD); Anemia, Kidney Disease, Chronic |
Mansoura University |
2025-04-01 | PHASE2 |
| NCT06111768 | COMPLETED | Cardiorenal Syndrome |
Yale University |
2024-05-30 | PHASE2 |
| NCT06344247 | UNKNOWN | Obesity; Chronic Kidney Diseases |
RenJi Hospital |
2023-09-01 | |
| NCT06888505 | COMPLETED | Anthracyclines-Induced Cardiotoxicity; Cardiotoxicity |
Hawler Medical University |
2024-09-01 | PHASE2 |
| NCT05833958 | WITHDRAWN | Type 2 Diabetes |
George Medicines PTY Limited |
2024-09 | PHASE2 |
| NCT07120828 | COMPLETED | Type 2 Diabetes; Obese Diabetics; Obese Patients (BMI ≥ 30 kg/m²) |
Erbil Polytechnic University |
2025-07-15 | PHASE4 |
| NCT06000462 | ACTIVE_NOT_RECRUITING | Obesity; Dapagliflozin Adverse Reaction; Weight Loss; Effect of Drug |
Oman Ministry of Health |
2024-04-22 | PHASE4 |
| NCT06919523 | NOT_YET_RECRUITING | Refractory Ascites |
Mansoura University |
2025-04-15 | PHASE2 |
| NCT05762952 | RECRUITING | Myocardial Ischemia |
University of Virginia |
2023-06-06 | PHASE1 |
| NCT06535529 | UNKNOWN | Acute Decompensated Heart Failure |
Helwan University |
2024-08-24 | PHASE3 |
| NCT06510270 | UNKNOWN | Heart Failure with Preserved Ejection Fraction |
Aswan University |
2024-08-01 | |
| NCT06778330 | COMPLETED | Heart Failure NYHA Class II |
Fayoum University |
2025-01-20 | |
| NCT06012266 | UNKNOWN | Heart Failure |
Centre Hospitalier Universitaire Vaudois |
2024-08 | PHASE2 |
| NCT04640493 | WITHDRAWN | Heart Failure; Sleep Disordered Breathing |
Columbia University |
2023-12 | PHASE2 |
| NCT06286878 | RECRUITING | Myocardial Infarction; Acute Coronary Syndrome; Diabetes; Ventricular Dysfunction |
University of Sao Paulo |
2021-12-08 | PHASE2; PHASE3 |
| NCT05468203 | TERMINATED | Acute Kidney Injury |
The George Institute |
2023-11-29 | PHASE3 |
| NCT06979388 | COMPLETED | Healthy Participants |
AstraZeneca |
2025-05-20 | PHASE1 |
| NCT05179668 | COMPLETED | Kidney Failure; Hemodialysis; Diabetes Mellitus, Type 2; Chronic Kidney Disease; Left Ventricular Hypertrophy |
Medical University of Vienna |
2022-10-01 | PHASE2 |
| NCT06783166 | RECRUITING | Acute Heart Failure |
Mansoura University |
2024-08-15 | PHASE2; PHASE3 |
| NCT06433479 | COMPLETED | Atrial Fibrillation |
Beijing Anzhen Hospital |
2024-07-15 | |
| NCT06327815 | COMPLETED | Type 2 Diabetes Mellitus (T2DM) |
AstraZeneca |
2024-03-15 | PHASE4 |
| NCT06415773 | COMPLETED | T2DM (Type 2 Diabetes Mellitus) |
Shenzhen HighTide Biopharmaceutical Ltd. |
2024-06-04 | PHASE3 |
| NCT04363697 | COMPLETED | Acute Heart Failure; Heart Failure |
The TIMI Study Group |
2020-09-24 | PHASE4 |
| NCT05435235 | SUSPENDED | Acute Kidney Injury; Percutaneous Coronary Intervention |
Albert Einstein Healthcare Network |
2024-09-01 | PHASE4 |
| NCT05795400 | COMPLETED | Heart Failure With Reduced Ejection Fraction; Heart Failure With Preserved Ejection Fraction; Heart Failure With Mid Range Ejection Fraction; Amyloid Cardiomyopathy |
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation |
2022-06-01 | |
| NCT06639087 | TERMINATED | Renal Impairment; Heart Failure |
AstraZeneca |
2024-09-27 | PHASE1 |
| NCT05590143 | ACTIVE_NOT_RECRUITING | Acute Kidney Injury; Cardiac Surgery; Sodium-Glucose Transporter 2 Inhibitor |
Amsterdam UMC |
2023-06-09 | PHASE4 |
| NCT06350123 | COMPLETED | Chronic Kidney Disease |
AstraZeneca |
2024-05-01 | PHASE2 |
| NCT06719661 | COMPLETED | Type 2 Diabetes Mellitus (T2DM) |
University of Sulaimani |
2024-12-01 | |
| NCT04707261 | UNKNOWN | Anemia; Heart Failure |
Xiangtan Central Hospital |
2021-08-06 | PHASE4 |
| NCT06421870 | UNKNOWN | Chronic Kidney Diseases |
Ain Shams University |
2024-03-01 | PHASE3 |
| NCT06341842 | UNKNOWN | Breast Cancer |
Fondazione IRCCS Policlinico San Matteo di Pavia |
2023-10-19 | PHASE2 |
| NCT07338331 | COMPLETED | Diabete Type 2; Non Alcoholic Fatty Liver |
Galala University |
2023-04-04 | |
| NCT06812429 | COMPLETED | Inflammation |
Washington University School of Medicine |
2024-05-08 | EARLY_PHASE1 |
| NCT06619600 | ACTIVE_NOT_RECRUITING | ST-segment Elevation Myocardial Infarction (STEMI); Diabetes Mellitus; Heart Failure; Myocardial Fibrosis |
Hospital Clinic of Barcelona |
2021-05-30 | PHASE3 |
| NCT05957887 | UNKNOWN | STEMI |
Mohamed Nabil Elkholy |
2022-04-15 | PHASE3 |
| NCT05570305 | COMPLETED | Chronic Kidney Diseases |
University Medical Center Groningen |
2022-10-06 | PHASE2 |
| NCT05359263 | RECRUITING | Chronic Kidney Diseases |
Tor Biering-Sørensen |
2022-06-08 | PHASE2 |
| NCT05139914 | TERMINATED | Diabetes Mellitus, Type 2; Endothelial Dysfunction |
Boston University |
2022-05-31 | PHASE4 |
| NCT06915870 | COMPLETED | Diabetes Mellitus; Heart Failure |
Fatima Maqsood |
2024-07-12 | |
| NCT06576375 | UNKNOWN | Polycystic Ovary Syndrome |
Future University in Egypt |
2024-09-02 | PHASE3 |
| NCT05565976 | UNKNOWN | Stroke, Ischemic; Mild Cognitive Impairment; Dementia, Vascular; Metabolic Syndrome |
Jaime Daniel Mondragon |
2020-08-01 | PHASE2; PHASE3 |
| NCT05443932 | UNKNOWN | Urolithiasis; Hyperoxaluria |
Medical University of Vienna |
2024-03-04 | PHASE4 |
| NCT06147518 | UNKNOWN | Compensated Cirrhosis; Decompensated Cirrhosis |
Institute of Liver and Biliary Sciences, India |
2023-12-20 | |
| NCT05194592 | UNKNOWN | Type2 Diabetes; Remodeling, Ventricular |
Wonju Severance Christian Hospital |
2022-01-07 | PHASE4 |
| NCT05050500 | COMPLETED | Myocardial Infarction; Diabete Type 2; Glucose Intolerance |
Qingdao Central Hospital |
2023-05-08 | PHASE4 |
| NCT04696185 | COMPLETED | Aortic Stenosis; Transcatether Aortic Valve Implantation |
Spanish Society of Cardiology |
2021-01-27 | PHASE4 |
| NCT06759077 | ACTIVE_NOT_RECRUITING | Kidney Diseases |
Al-Azhar University |
2024-12-28 | PHASE3 |
| NCT06269484 | COMPLETED | Liver Cirrhosis |
AstraZeneca |
2024-02-15 | PHASE2 |
| NCT05042505 | COMPLETED | Diabetes Mellitus; Liver Transplant; Complications |
Medanta, The Medicity, India |
2022-01-01 | |
| NCT06113900 | UNKNOWN | Lupus Nephritis |
Ain Shams University |
2023-12-01 | PHASE1; PHASE2 |
| NCT06065280 | COMPLETED | Heart Failure; Reduced Ejection Fraction Heart Failure |
Damanhour University |
2022-11-01 | |
| NCT05713851 | UNKNOWN | AKI - Acute Kidney Injury; Biomarkers; Transition to CKD; CKD |
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
2023-01-01 | PHASE2; PHASE3 |
| NCT05676684 | COMPLETED | Heart Failure With Preserved Ejection Fraction |
Universidade do Porto |
2022-09-15 | PHASE2; PHASE3 |
| NCT05792540 | COMPLETED | Depressive Disorder |
Tanta University |
2023-06-06 | PHASE2 |
| NCT05550441 | UNKNOWN | Heart Failure |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2022-11-15 | PHASE4 |
| NCT05685394 | UNKNOWN | End-stage Kidney Disease |
University of Campinas, Brazil |
2023-01-24 | PHASE4 |
| NCT05058859 | WITHDRAWN | Cystinuria |
University of California, San Francisco |
2023-09-01 | PHASE2 |
| NCT05848102 | UNKNOWN | Functional Mitral Regurgitation |
Sun Yat-sen University |
2022-12-23 | PHASE4 |
| NCT05998837 | COMPLETED | Chronic Kidney Disease; Diabetes Mellitus, Type 2; Hypertension |
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy |
2021-04-13 | PHASE2; PHASE3 |
| NCT05776043 | UNKNOWN | Acute Decompensated Heart Failure |
Medical University of Warsaw |
2022-03-15 | PHASE3 |
| NCT04869124 | COMPLETED | Heart Failure，Congestive |
Frank Ruschitzka |
2021-02-15 | PHASE4 |
| NCT04930549 | COMPLETED | Renal Insufficiency, Chronic |
University Hospital, Rouen |
2022-10-18 | PHASE2 |
| NCT05196347 | COMPLETED | Chronic Kidney Diseases |
Kaohsiung Medical University |
2022-05-27 | PHASE3 |
| NCT06365541 | UNKNOWN | The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients |
The People's Hospital of Gaozhou |
2024-03-01 | PHASE4 |
| NCT04965935 | COMPLETED | Kidney Transplant Recipients; Post-transplant Diabetes Mellitus; Type 2 Diabetes |
University Health Network, Toronto |
2021-07-15 | PHASE3 |
| NCT06233045 | UNKNOWN | Healthy Subjects |
Bio-innova Co., Ltd |
2024-07-23 | PHASE1 |
| NCT07077525 | COMPLETED | Type 2 Diabetes |
Al-Azhar University |
2023-06-01 | PHASE4 |
| NCT05710367 | UNKNOWN | Fabry Disease |
Albina Nowak, MD |
2023-08 | PHASE2 |
| NCT06012266 | Not yet recruiting | Heart Failure |
Centre Hospitalier Universitaire Vaudois|Great Ormond Street Hospital for Children NHS Foundation Trust|University College London |
2024-08 | Phase 2 |
| NCT03968224 | COMPLETED | PreDiabetes; Obesity, Morbid; Diabetes Mellitus, Type 2 |
Centro Medico Nacional Siglo XXI IMSS |
2018-08-04 | PHASE2; PHASE3 |
| NCT05459701 | COMPLETED | Nonalcoholic Fatty Liver Disease; Type 2 Diabetes |
Rehab Werida |
2022-05-01 | PHASE4 |
| NCT05621551 | COMPLETED | Diabetes Mellitus, Type 2; Cardiac Surgery |
China National Center for Cardiovascular Diseases |
2022-11-11 | PHASE4 |
| NCT04794517 | COMPLETED | Chronic Kidney Diseases |
Mario Negri Institute for Pharmacological Research |
2021-11-08 | PHASE2 |
| NCT06127433 | UNKNOWN | Insulin Pump，Continuous Glucose Monitoring Technology |
Sun Yat-sen University |
2023-03-07 | PHASE4 |
| NCT05686616 | UNKNOWN | Tricuspid Regurgitation |
Samsung Medical Center |
2022-04-13 | |
| NCT06336330 | Recruiting | Heart Diseases|Cardiovascular Diseases|Heart Failure |
AstraZeneca |
2024-04-25 | -- |
| NCT04887935 | Not yet recruiting | Prostate Cancer|Cancer of Prostate |
Washington University School of Medicine|The Foundation for Barnes-Jewish Hospital |
2024-04-30 | Phase 1 |
| NCT04782245 | WITHDRAWN | End-stage Heart Failure |
Hospices Civils de Lyon |
2022-09 | PHASE2 |
| NCT06398977 | Recruiting | Peritoneal Dialysis Complication|Renal Function Aggravated|Sodium-glucose Co-transporter-2 Inhibitors |
Sichuan Academy of Medical Sciences |
2024-03-11 | Not Applicable |
| NCT05505994 | UNKNOWN | Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose Metabolism Disorders; Metabolic Disease; Endocrine System Diseases |
Daewoong Pharmaceutical Co. LTD. |
2022-09-28 | PHASE3 |
| NCT06012279 | COMPLETED | Acute Heart Failure |
Cairo University |
2023-08-01 | PHASE4 |
| NCT05254626 | COMPLETED | Non-alcoholic Steatohepatitis |
Cairo University |
2022-08-01 | PHASE2 |
| NCT03919656 | COMPLETED | Type 2 Diabetes Mellitus |
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud |
2019-05-12 | PHASE4 |
| NCT05704088 | COMPLETED | SGLT2 INHIBITORS; Lupus Nephritis; BMD |
Mansoura University |
2022-10-08 | PHASE4 |
| NCT03499704 | COMPLETED | Diabetes Mellitus, Type 2 |
Celltrion Pharm, Inc. |
2020-02-11 | PHASE4 |
| NCT05390307 | COMPLETED | Type 1 Diabetes |
Dasman Diabetes Institute |
2023-04-01 | |
| NCT05748925 | COMPLETED | SLE; Lupus Nephritis; SGLT2 Inhibitors |
Mansoura University |
2022-10-01 | PHASE4 |
| NCT04783870 | UNKNOWN | Myocardial Infarction |
Instituto Mexicano del Seguro Social |
2021-03-03 | PHASE4 |
| NCT05162690 | UNKNOWN | Diabetic Peripheral Neuropathy |
Post Graduate Institute of Medical Education and Research, Chandigarh |
2022-05-01 | PHASE2; PHASE3 |
| NCT04796428 | UNKNOWN | Diabetes Mellitus, Type 2 |
Center for Outcomes Research and Clinical Epidemiology, Italy |
2021-06-30 | PHASE4 |
| NCT05262257 | UNKNOWN | Type2 Diabetes |
The First Affiliated Hospital with Nanjing Medical University |
2022-04-01 | EARLY_PHASE1 |
| NCT06383832 | COMPLETED | Overweight; Carbohydrate; Sodium-glucose Transporter 2 Inhibitors |
Sun Jia |
2021-10-28 | PHASE4 |
| NCT06721442 | COMPLETED | Arrhythmias, Cardiac; Diabetes Mellitus |
Beneficência Portuguesa de São Paulo |
2023-01-10 | PHASE4 |
| NCT06063109 | COMPLETED | Hypertension; Diabetes Mellitus, Type 2 |
THPharm Corp. |
2023-10-09 | PHASE1 |
| NCT07344922 | COMPLETED | Chronic Kidney Disease; Anemia; Cardiovascular Calcification |
Mansoura University |
2022-09-01 | PHASE3 |
| NCT05915949 | UNKNOWN | Diabetes Type 2 |
Seoul National University Bundang Hospital |
2022-01-01 | PHASE4 |
| NCT02879409 | ACTIVE_NOT_RECRUITING | Diabetes Mellitus Type 2 |
Weill Cornell Medical College in Qatar |
2016-11 | |
| NCT05335629 | COMPLETED | Myocardial Infarction; Diabetes Mellitus, Type 2; Myocardial Remodeling, Ventricular |
Ain Shams University |
2022-06-01 | |
| NCT04595370 | COMPLETED | Heart Failure; Chronic Kidney Disease |
AstraZeneca |
2021-01-26 | PHASE2 |
| NCT04780438 | UNKNOWN | Atrial Fibrillation Recurrent; Pulmonary Venous Isolation; Catheter Ablation; Sodium-glucose Co-transporter 2 Inhibitors |
G.Gennimatas General Hospital |
2021-09-01 | EARLY_PHASE1 |
| NCT05420285 | UNKNOWN | Heart Failure; Reduced Ejection Fraction |
Assistance Publique - Hôpitaux de Paris |
2022-06-26 | PHASE2 |
| NCT07363707 | COMPLETED | NAFLD (Nonalcoholic Fatty Liver Disease) |
Beni-Suef University |
2023-05-01 | PHASE4 |
| NCT03762850 | ACTIVE_NOT_RECRUITING | Immunoglobulin A Nephropathy |
Travere Therapeutics, Inc. |
2018-12-11 | PHASE3 |
| NCT05717257 | UNKNOWN | Dapagliflozin Adverse Reaction; Efficacy; Systemic Right Ventricle |
Monaldi Hospital |
2022-08-01 | PHASE4 |
| NCT05601336 | UNKNOWN | PCO |
Beni-Suef University |
2022-01-15 | PHASE3 |
| NCT02911792 | COMPLETED | Diabetes Mellitus, Type 2 |
The University of Texas Health Science Center at San Antonio |
2016-12-20 | PHASE4 |
| NCT04564742 | COMPLETED | Acute Myocardial Infarction; Heart Failure |
AstraZeneca |
2020-12-22 | PHASE3 |
| NCT05308160 | UNKNOWN | Fatty Liver |
National Taiwan University Hospital |
2021-06-28 | PHASE3 |
| NCT05606718 | UNKNOWN | Functional Mitral Regurgitation |
Sun Yat-sen University |
2022-04-01 | PHASE4 |
| NCT04956809 | COMPLETED | HFrEF |
University of Pennsylvania |
2021-10-22 | PHASE2 |
| NCT05618223 | UNKNOWN | Rheumatic Heart Disease; Heart Failure; Mitral Stenosis |
Universitas Sebelas Maret |
2022-12-01 | PHASE3 |
| NCT04620590 | COMPLETED | Diabetes Mellitus, Type 2; Impaired Renal Function |
Emerald Clinical Inc. |
2021-04-20 | PHASE4 |
| NCT04170543 | COMPLETED | Diabetic Kidney Disease |
AstraZeneca |
2019-11-18 | PHASE2 |
| NCT05440591 | UNKNOWN | Diabetes |
Tan Tock Seng Hospital |
2019-04-01 | PHASE4 |
| NCT04899349 | TERMINATED | Breast Cancer |
Novartis Pharmaceuticals |
2022-04-06 | PHASE2 |
| NCT05406505 | COMPLETED | Acute Heart Failure |
Mansoura University |
2022-04-25 | PHASE2; PHASE3 |
| NCT05310916 | UNKNOWN | Diabetic Retinopathy |
Nidae Alaa |
2022-06-06 | PHASE3 |
| NCT04049110 | COMPLETED | Diabetes Mellitus, Type 1 |
Insel Gruppe AG, University Hospital Bern |
2020-08-25 | PHASE3 |
| NCT04792190 | COMPLETED | Atrial Fibrillation |
University of Rochester |
2021-07-27 | PHASE4 |
| NCT04707352 | COMPLETED | Heart Failure |
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia |
2021-02-08 | PHASE3 |
| NCT06127212 | COMPLETED | Healthy |
Dexa Medica Group |
2023-03-08 | |
| NCT04445714 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2021-04-07 | PHASE4 |
| NCT05429593 | COMPLETED | Healthy Volunteers |
Novo Nordisk A/S |
2022-06-22 | PHASE1 |
| NCT03423355 | WITHDRAWN | Type 2 Diabetes Mellitus (T2DM) |
University Hospital Tuebingen |
2021-09 | PHASE4 |
| NCT05268926 | TERMINATED | Albuminuria |
University Medical Center Groningen |
2022-02-03 | PHASE2 |
| NCT03199053 | COMPLETED | Diabetes Mellitus, Type 2 |
AstraZeneca |
2017-10-11 | PHASE3 |
| NCT04004793 | COMPLETED | Type 2 Diabetes |
Shanghai Zhongshan Hospital |
2020-06-12 | PHASE4 |
| NCT05457933 | COMPLETED | Type2diabetes; Coronary Artery Disease |
Medanta, The Medicity, India |
2022-07-29 | PHASE4 |
| NCT06326034 | COMPLETED | Diabetic Nephropathy Type 2 |
Mohammed Mahmood Mohammed |
2022-05-01 | PHASE4 |
| NCT05418465 | UNKNOWN | Diabetic Nephropathies |
The First Affiliated Hospital of Dalian Medical University |
2022-01-26 | |
| NCT05225077 | UNKNOWN | Renal Insufficiency, Chronic; Cardiac Catheterization; Percutaneous Coronary Intervention |
Dong-A University |
2022-01-01 | PHASE4 |
| NCT04739215 | UNKNOWN | Diabetes Mellitus, Type 2; Heart Failure With Preserved Ejection Fraction |
Hospital General Universitario Gregorio Marañon |
2021-01-15 | PHASE4 |
| NCT05998525 | COMPLETED | Diabete Type 2; Unstable Angina; Myocardial Infarction; Diabetes Mellitus, Type 2 |
Hilda Elizabeth Macías Cervantes |
2021-06-21 | PHASE3 |
| NCT05797935 | COMPLETED | Pancreatic Lipomatosis |
Post Graduate Institute of Medical Education and Research, Chandigarh |
2021-08-01 | PHASE4 |
| NCT05025735 | UNKNOWN | Metastatic Breast Cancer; HER2-negative Breast Cancer |
Saint Luke's Health System |
2021-08-25 | PHASE2 |
| NCT05591235 | UNKNOWN | Type2diabetes; Insulin Resistance |
Nanjing First Hospital, Nanjing Medical University |
2022-11 | PHASE3 |
| NCT04730947 | COMPLETED | Heart Failure With Preserved Ejection Fraction |
Mayo Clinic |
2021-02-24 | PHASE2 |
| NCT03782259 | COMPLETED | Type 2 Diabetes Mellitus; Myocardial Fibrosis; Myocardial Inflammation |
University of Washington |
2019-02-26 | PHASE4 |
| NCT04860011 | UNKNOWN | Heart Failure |
NHS Greater Glasgow and Clyde |
2021-04-27 | PHASE3 |
| NCT03313752 | COMPLETED | Type2 Diabetes Mellitus; Stable Coronary Artery Disease |
Giaccari Andrea |
2017-12-01 | PHASE3 |
| NCT05159882 | UNKNOWN | T2DM |
Newsoara Biopharma Co., Ltd. |
2021-04-15 | PHASE3 |
| NCT04885712 | COMPLETED | Type2 Diabetes |
Boryung Pharmaceutical Co., Ltd |
2021-05-28 | PHASE3 |
| NCT04401904 | COMPLETED | Aging |
The University of Texas Health Science Center at San Antonio |
2020-06-25 | PHASE1; PHASE2 |
| NCT06374043 | COMPLETED | Diabetes Mellitus, Type 2; Diabetes Mellitus Type 2 With Proteinuria; Diabetes Mellitus; Diabetes; Diabetes Complications; Albuminuria; Chronic Kidney Diseases; Chronic Kidney Disease Due to Type 2 Diabetes Mellitus; CKD; Proteinuria |
University Medical Center Groningen |
2021-05-11 | PHASE4 |
| NCT04492722 | TERMINATED | Chronic Kidney Disease |
AstraZeneca |
2020-10-01 | PHASE2 |
| NCT05343078 | COMPLETED | End-stage Renal Disease |
University of Campinas, Brazil |
2022-04-25 | PHASE4 |
| NCT03714594 | COMPLETED | Type2 Diabetes Mellitus |
University of Pisa |
2018-07-24 | PHASE2 |
| NCT04234867 | TERMINATED | Type 1 Diabetes; Diabetic Ketoacidosis |
Kinderkrankenhaus auf der Bult |
2022-05-18 | PHASE1 |
| NCT04778787 | COMPLETED | Congestive Heart Failure |
I.M. Sechenov First Moscow State Medical University |
2021-01-01 | PHASE4 |
| NCT02981069 | COMPLETED | Diabetes Mellitus, Type 2 |
The University of Texas Health Science Center at San Antonio |
2017-12-15 | PHASE4 |
| NCT03801642 | COMPLETED | Alzheimer Disease |
Jeff Burns, MD |
2019-01-29 | PHASE1; PHASE2 |
| NCT04717986 | COMPLETED | Acute Myocardial Infarction; Cardiovascular Morbidity; Heart Failure; Angina, Unstable |
Instituto Mexicano del Seguro Social |
2021-01-26 | |
| NCT04400760 | COMPLETED | Platelet Dysfunction |
The University of The West Indies |
2020-05-01 | PHASE2; PHASE3 |
| NCT05330013 | WITHDRAWN | Myocardial Dysfunction; Heart Failure; Inflammation |
National Heart, Lung, and Blood Institute (NHLBI) |
2022-06-23 | PHASE2 |
| NCT05109949 | UNKNOWN | Diabetes Mellitus Type 2 Without Complication |
Centro Universitario de Ciencias de la Salud, Mexico |
2020-03-30 | PHASE3 |
| NCT04340908 | UNKNOWN | Diabetes Mellitus, Type 2; Cardiac Surgery |
Hongchang Guo |
2021-01-01 | PHASE4 |
| NCT04531397 | WITHDRAWN | Proteinuria; Chronic Kidney Diseases |
Children's Hospital of Fudan University |
2021-01-01 | PHASE4 |
| NCT04393246 | COMPLETED | COVID-19 |
Cambridge University Hospitals NHS Foundation Trust |
2020-07-03 | PHASE2; PHASE3 |
| NCT05045274 | UNKNOWN | STEMI - ST Elevation Myocardial Infarction; Left Ventricular Systolic Dysfunction |
Assiut University |
2021-12 | |
| NCT05266404 | COMPLETED | Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus) |
AstraZeneca |
2022-03-21 | PHASE1 |
| NCT05014594 | UNKNOWN | Cirrhosis; Ascites Hepatic |
Post Graduate Institute of Medical Education and Research, Chandigarh |
2021-09-03 | PHASE2 |
| NCT05424315 | COMPLETED | Anterior MI |
Omar Younis |
2021-10-01 | PHASE2; PHASE3 |
| NCT02981966 | COMPLETED | Diabetes Mellitus, Type 2 |
The University of Texas Health Science Center at San Antonio |
2019-05-23 | PHASE4 |
| NCT03331289 | COMPLETED | Diabetes Mellitus, Type 2 |
The University of Texas Health Science Center at San Antonio |
2018-02-28 | PHASE4 |
| NCT03619213 | COMPLETED | Heart Failure With Preserved Ejection Fraction |
AstraZeneca |
2018-08-27 | PHASE3 |
| NCT04249778 | COMPLETED | Heart Failure; Diabetes |
Emory University |
2020-07-29 | PHASE4 |
| NCT04545411 | COMPLETED | Type 1 Diabetes |
University of California, San Diego |
2021-02-22 | PHASE1; PHASE2 |
| NCT05105698 | UNKNOWN | Healthy Volunteers |
LG Chem |
2022-01-01 | PHASE1 |
| NCT05250752 | UNKNOWN | End Stage Renal Disease; Peritoneal Dialysis Complication |
Holbaek Sygehus |
2021-11-18 | PHASE2 |
| NCT04956263 | COMPLETED | Diabetes; Diabetes Mellitus, Type 1; Type1diabetes; Diabetes Mellitus |
Youngene Therapeutics Inc., Ltd. |
2021-06-17 | PHASE2 |
| NCT04534270 | COMPLETED | Proteinuria |
Children's Hospital of Fudan University |
2020-07-06 | PHASE4 |
| NCT04542291 | COMPLETED | Pancreas Cancer; Pancreatic Cancer; Cancer of the Pancreas |
Washington University School of Medicine |
2021-02-25 | PHASE1 |
| NCT05236998 | COMPLETED | Healthy Subjects |
SK Chemicals Co., Ltd. |
2021-11-03 | PHASE1 |
| NCT04451837 | ACTIVE_NOT_RECRUITING | Type2 Diabetes |
Region Skane |
2020-09-10 | PHASE2 |
| NCT04818034 | COMPLETED | Cystinuria |
University of California, San Francisco |
2021-08-30 | PHASE2 |
| NCT04570865 | UNKNOWN | Heart Failure, Systolic |
Scripps Health |
2020-12-01 | PHASE4 |
| NCT02338921 | COMPLETED | Type 2 Diabetes |
Seoul National University Bundang Hospital |
2015-01 | PHASE4 |
| NCT04080518 | COMPLETED | Diabetes Mellitus; Heart Failure |
National Heart Centre Singapore |
2019-11-11 | PHASE4 |
| NCT04634500 | COMPLETED | T2DM (Type 2 Diabetes Mellitus) |
Daewoong Pharmaceutical Co. LTD. |
2020-11-18 | PHASE3 |
| NCT04475042 | UNKNOWN | Heart Failure, Diastolic |
Mariëlle Scheffer |
2020-07-01 | PHASE2 |
| NCT04991571 | COMPLETED | Chronic Kidney Disease |
AstraZeneca |
2021-07-29 | PHASE1 |
| NCT04798222 | COMPLETED | Heart Failure |
AstraZeneca |
2021-06-29 | PHASE1 |
| NCT04197635 | COMPLETED | Heart Failure With Reduced Ejection Fraction |
Fundación para la Investigación del Hospital Clínico de Valencia |
2019-06-01 | PHASE4 |
| NCT03030235 | COMPLETED | Chronic Heart Failure With Preserved Systolic Function |
Saint Luke's Health System |
2017-03-01 | PHASE4 |
| NCT04923295 | COMPLETED | Peritoneal Dialysis Complication; Ultrafiltration Failure |
An-Najah National University |
2021-06-02 | |
| NCT03537131 | TERMINATED | Diabetes Mellitus, Type 1 |
University of Oxford |
2018-06-02 | PHASE2 |
| NCT03721874 | COMPLETED | Prediabetic State; Substrate Oxidation |
Maastricht University |
2019-04-30 | PHASE4 |
| NCT04170998 | COMPLETED | Type2 Diabetes |
Dong-A ST Co., Ltd. |
2020-01-02 | PHASE3 |
| NCT04856007 | COMPLETED | Healthy Volunteer |
AstraZeneca |
2021-04-12 | PHASE1 |
| NCT03970044 | COMPLETED | Diabetes Mellitus, Type 2 |
Consano Clinical Research, LLC |
2019-07-02 | PHASE4 |
| NCT03842267 | COMPLETED | Diabetes Mellitus, Type 2 |
LG Chem |
2019-05-13 | PHASE3 |
| NCT03269058 | COMPLETED | Type-2 Diabetes; Oral Antidiabetics |
Centre Hospitalier Universitaire Dijon |
2017-12-20 | PHASE4 |
| NCT04856969 | COMPLETED | Healthy Adult Volunteers |
Autotelicbio |
2021-03-30 | PHASE1 |
| NCT04330079 | TERMINATED | Coronary Artery Disease; Prediabetic State |
CHEOL WHAN LEE, M.D., Ph.D |
2020-05-21 | PHASE4 |
| NCT04350593 | COMPLETED | COVID-19 |
Saint Luke's Health System |
2020-04-22 | PHASE3 |
| NCT03660683 | TERMINATED | Diabetes Mellitus, Type 2; Cardiovascular Diseases |
Sabyasachi Sen |
2018-10-22 | PHASE4 |
| NCT04090580 | COMPLETED | Type 2 Diabetes |
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
2019-10-27 | PHASE3 |
| NCT04200586 | UNKNOWN | Type2 Diabetes; Heart Failure With Reduced Ejection Fraction |
The University of Hong Kong |
2020-04-09 | PHASE4 |
| NCT04287387 | UNKNOWN | Type2 Diabetes Mellitus |
Peking Union Medical College Hospital |
2020-03-02 | PHASE4 |
| NCT04304560 | UNKNOWN | Heart Failure With Reduced Ejection Fraction (HFrEF); Diabete Type 2; Cardiomyopathies |
Damanhour University |
2020-03 | PHASE2 |
| NCT04544319 | UNKNOWN | T2DM |
LG Chem |
2020-10 | PHASE1 |
| NCT02962492 | COMPLETED | Evaluate Ketogenic Stress |
University at Buffalo |
2016-11-01 | |
| NCT03658031 | UNKNOWN | PreDiabetes; Myocardial Infarction; T2DM (Type 2 Diabetes Mellitus); CVD |
Hamad Medical Corporation |
2019-03-01 | PHASE3 |
| NCT04880993 | COMPLETED | Healthy Subjects |
Jiangsu Hansoh Pharmaceutical Co., Ltd. |
2020-12-14 | PHASE1 |
| NCT04881006 | COMPLETED | Healthy Subjects |
Jiangsu Hansoh Pharmaceutical Co., Ltd. |
2020-12-10 | PHASE1 |
| NCT04385589 | COMPLETED | Heart Failure |
Assiut University |
2020-05-01 | PHASE4 |
| NCT04035031 | COMPLETED | Diabetes Mellitus, Type 1 |
Insel Gruppe AG, University Hospital Bern |
2020-01-09 | PHASE3 |
| NCT05066516 | COMPLETED | Diabetes Mellitus |
Korea University Anam Hospital |
2020-06-25 | PHASE1 |
| NCT03608358 | TERMINATED | Type 2 Diabetes Mellitus |
AstraZeneca |
2019-02-27 | PHASE3 |
| NCT03961659 | UNKNOWN | Type 2 Diabetes Mellitus; Obesity; Cognitive Impairment |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
2019-05 | |
| NCT04014192 | UNKNOWN | Type 2 Diabetes Mellitus |
Peking Union Medical College Hospital |
2019-09-01 | PHASE4 |
| NCT02635386 | COMPLETED | Polycystic Ovary Syndrome; Obesity |
Woman's |
2016-03-22 | PHASE3 |
| NCT03877224 | COMPLETED | Heart Failure With Preserved Ejection Fraction (HFpEF) |
AstraZeneca |
2019-04-04 | PHASE3 |
| NCT02751398 | COMPLETED | Type 2 Diabetes Mellitus |
Yonsei University |
2016-08-18 | PHASE4 |
| NCT02725593 | COMPLETED | Type 2 Diabetes |
AstraZeneca |
2016-06-22 | PHASE3 |
| NCT03152084 | TERMINATED | Diabetes Mellitus, Type 2; Kidney Function Tests |
AstraZeneca |
2017-07-12 | PHASE4 |
| NCT03877237 | COMPLETED | Heart Failure With Reduced Ejection Fraction (HFrEF) |
AstraZeneca |
2019-04-09 | PHASE3 |
| NCT02965443 | TERMINATED | Type 2 Diabetes |
University Hospital Tuebingen |
2018-02-02 | PHASE4 |
| NCT04120623 | UNKNOWN | Type 2 Diabetes Mellitus |
Nanjing First Hospital, Nanjing Medical University |
2019-10-01 | PHASE4 |
| NCT04242758 | UNKNOWN | Renal Function Disorder; Glucose Metabolism Disorders |
University of Pisa |
2019-06-04 | PHASE4 |
| NCT03700801 | COMPLETED | Type 2 Diabetes Mellitus |
Zhujiang Hospital |
2018-10-01 | PHASE4 |
| NCT03556033 | COMPLETED | Diabetes Mellitus, Type 1; Hypoglycemia; Hypoglycemia Unawareness |
Radboud University Medical Center |
2018-11-23 | PHASE2 |
| NCT02946632 | UNKNOWN | Diabetes Mellitus, Type II |
Korea University Anam Hospital |
2016-12 | PHASE3 |
| NCT03007329 | COMPLETED | Steatosis, Liver; Type2 Diabetes |
Medical University of Vienna |
2017-03-08 | PHASE4 |
| NCT03361098 | COMPLETED | Type 2 Diabetes Mellitus; Obesity |
Amsterdam UMC, location VUmc |
2017-09-18 | PHASE4 |
| NCT03982238 | COMPLETED | Type 2 Diabetes |
Majianhua |
2019-06-15 | PHASE4 |
| NCT03338855 | COMPLETED | Diabetes Mellitus, Type 2; Skeletal Muscle Insulin Sensitivity |
AstraZeneca |
2018-03-05 | PHASE4 |
| NCT03190694 | COMPLETED | Chronic Kidney Diseases; Proteinuria |
Hiddo Lambers Heerspink |
2017-11-12 | PHASE2 |
| NCT02973477 | COMPLETED | Type2 Diabetes; Cardiovascular Diseases |
University of Michigan |
2017-01-12 | PHASE4 |
| NCT03036124 | COMPLETED | Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) |
AstraZeneca |
2017-02-08 | PHASE3 |
| NCT03344341 | TERMINATED | Type 2 Diabetes Mellitus |
AstraZeneca |
2017-12-15 | PHASE4 |
| NCT03364985 | COMPLETED | Healthy |
Daewoong Pharmaceutical Co. LTD. |
2017-12-03 | PHASE1 |
| NCT03419624 | TERMINATED | Obesity; Diabetes Mellitus, Type 2 |
Universitätsklinikum Hamburg-Eppendorf |
2018-02-19 | PHASE3 |
| NCT03387683 | COMPLETED | Diabetes Mellitus Type 2 |
AstraZeneca |
2018-02-28 | PHASE4 |
| NCT02956811 | COMPLETED | Type 2 Diabetes; Left Ventricular Hypertrophy |
University of Dundee |
2017-02-14 | PHASE4 |
| NCT02338193 | COMPLETED | Diabetes Prevention in Women After GDM Who Are at High-risk |
Woman's |
2015-09-22 | PHASE3 |
| NCT03766724 | COMPLETED | Type2 Diabetes |
Dong-A ST Co., Ltd. |
2018-11-22 | PHASE1 |
| NCT03180489 | COMPLETED | Weight Loss |
Christopher Bell |
2017-05-03 | PHASE2 |
| NCT03444584 | COMPLETED | Type 2 Diabetes Mellitus |
MedImmune LLC |
2018-05-08 | PHASE2 |
| NCT02919345 | COMPLETED | Diabetes Mellitus, Type 2; Coronary Artery Disease; Carotid Artery Diseases |
University of Campinas, Brazil |
2017-01 | PHASE4 |
| NCT02919059 | UNKNOWN | Diabetes Mellitus, Type 2 |
IInstituto Gallego de Medicina Vascular |
2016-12-13 | PHASE4 |
| NCT02984644 | COMPLETED | Type II; Diabetes |
The University of Texas Health Science Center at San Antonio |
2017-09-06 | PHASE3 |
| NCT02592421 | COMPLETED | Type II Diabetes Mellitus |
The University of Texas Health Science Center at San Antonio |
2015-10-23 | PHASE3 |
| NCT02695810 | COMPLETED | Prediabetic State; Obesity |
Steno Diabetes Center Copenhagen |
2016-02-24 | PHASE2 |
| NCT03398577 | UNKNOWN | Coronary Disease With Diabetes Mellitus |
Sheba Medical Center |
2018-02-01 | PHASE4 |
| NCT03565458 | UNKNOWN | Type 2 Diabetes Mellitus |
LG Chem |
2018-04-05 | PHASE1 |
| NCT02798757 | COMPLETED | Diabetes |
University of Ioannina |
2016-06 | PHASE4 |
| NCT03316131 | COMPLETED | Asymptomatic Hyperuricemia |
AstraZeneca |
2017-10-25 | PHASE2 |
| NCT02610088 | COMPLETED | Diabetes |
Seoul National University Bundang Hospital |
2015-11 | PHASE4 |
| NCT03178591 | COMPLETED | Diabetes Mellitus, Type 2; Ischemic Heart Disease |
Chiang Mai University |
2014-10 | PHASE4 |
| NCT02811484 | WITHDRAWN | Diabetes Mellitus, Type 2 |
Weill Medical College of Cornell University |
2016-06 | PHASE4 |
| NCT03216278 | COMPLETED | Healthy Subjects in Fasted and Fed State |
AstraZeneca |
2017-09-26 | PHASE1 |
| NCT02547935 | COMPLETED | Type 2 Diabetes Mellitus, CKD and Albuminuria |
AstraZeneca |
2015-09-21 | PHASE2; PHASE3 |
| NCT03074630 | COMPLETED | Diabetes Mellitus, Type 2; Hypercholesterolemia |
Amsterdam UMC, location VUmc |
2016-05 | PHASE4 |
| NCT03006471 | COMPLETED | PreDiabetes; Prehypertension |
University of Guadalajara |
2016-03-30 | PHASE4 |
| NCT02925559 | COMPLETED | Diabetes Mellitus, Type 2 |
Centro de Diabetes Curitiba Ltda |
2016-10 | PHASE4 |
| NCT02564926 | COMPLETED | Diabetes Mellitus, Type 2 |
AstraZeneca |
2016-01-05 | PHASE4 |
| NCT02371187 | COMPLETED | Physical Activity |
Christopher Bell |
2015-06 | PHASE2 |
| NCT02577159 | UNKNOWN | Diabetes Mellitus, Type 2 |
Osaka University |
2015-07-01 | PHASE4 |
| NCT02987738 | COMPLETED | Type1diabetes |
Kinderkrankenhaus auf der Bult |
2017-02-09 | PHASE1 |
| NCT02558270 | UNKNOWN | Type 2 Diabetes; Metabolically Healthy Controls |
Medical University of Vienna |
2016-06 | PHASE2 |
| NCT02719132 | WITHDRAWN | Diabetes Mellitus Type 2 |
AstraZeneca |
2016-07 | PHASE4 |
| NCT02532855 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2015-10-20 | PHASE3 |
| NCT02460978 | COMPLETED | Type 1 Diabetes Mellitus |
AstraZeneca |
2015-07-08 | PHASE3 |
| NCT02419612 | COMPLETED | Diabetes |
AstraZeneca |
2015-08-14 | PHASE3 |
| NCT03169959 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2017-05-29 | PHASE1 |
| NCT02397421 | COMPLETED | Heart Failure; Diabetes |
University of Dundee |
2015-03 | PHASE4 |
| NCT02681094 | COMPLETED | Type 2 Diabetes Mellitus; Inadequate Glycaemic Control |
AstraZeneca |
2016-02-26 | PHASE3 |
| NCT02914691 | COMPLETED | Type 2 Diabetes; Diabetic Nephropathy |
Peter Rossing |
2015-08 | PHASE4 |
| NCT02582814 | COMPLETED | Type 1 Diabetes Mellitus |
AstraZeneca |
2015-10-26 | PHASE3 |
| NCT02475070 | COMPLETED | Type 2 Diabetes |
Lund University |
2016-01 | PHASE4 |
| NCT02551874 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2015-10-20 | PHASE3 |
| NCT02471404 | COMPLETED | Type 2 Diabetes Mellitus; Inadequate Glycaemic Control |
AstraZeneca |
2015-09-21 | PHASE4 |
| NCT02268214 | COMPLETED | Type 1 Diabetes Mellitus |
AstraZeneca |
2014-11-11 | PHASE3 |
| NCT02700334 | COMPLETED | Prediabetes; Impaired Fasting Glucose; Impaired Glucose Tolerance |
University of Guadalajara |
2016-10 | PHASE4 |
| NCT02777073 | COMPLETED | Type 1 Diabetes |
University at Buffalo |
2016-03-01 | |
| NCT02765204 | COMPLETED | Diabetes Mellitus, Type 2 |
Uppsala University |
2016-03 | PHASE4 |
| NCT02284893 | COMPLETED | Type 2 Diabetes |
AstraZeneca |
2014-09-09 | PHASE3 |
| NCT02327039 | COMPLETED | Type 2 Diabetes |
University of Padova |
2015-03 | PHASE4 |
| NCT02211742 | COMPLETED | Fasting Glucose; Glucose Excursion; Glycemic Control |
Medical University Innsbruck |
2014-08 | PHASE4 |
| NCT02582840 | COMPLETED | Type 1 Diabetes Mellitus |
AstraZeneca |
2015-10 | PHASE1 |
| NCT02426541 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2015-03-23 | PHASE4 |
| NCT02229396 | COMPLETED | Diabetes Mellitus |
AstraZeneca |
2014-09-04 | PHASE3 |
| NCT02637037 | COMPLETED | Bioequivalence; Fixed Dose Combination Tablets; Healthy Male and Female Subjects |
AstraZeneca |
2015-12-21 | PHASE1 |
| NCT02253121 | COMPLETED | Hyperglycemia Steroid-induced |
Slotervaart Hospital |
2015-02 | PHASE4 |
| NCT02313220 | COMPLETED | Obesity |
Uppsala University |
2014-12 | PHASE2 |
| NCT02372955 | UNKNOWN | Diabetes Mellitus Type 2 |
Gulf Regional Research & Educational Services, LLC |
2015-02 | PHASE4 |
| NCT02096705 | COMPLETED | Diabetes |
AstraZeneca |
2014-03-31 | PHASE3 |
| NCT02518945 | COMPLETED | Type 1 Diabetes Mellitus |
University at Buffalo |
2015-08 | PHASE3 |
| NCT02325206 | COMPLETED | Type 1 Diabetes |
Kinderkrankenhaus auf der Bult |
2014-12 | PHASE1 |
| NCT02279407 | COMPLETED | T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin) |
AstraZeneca |
2015-01 | PHASE2 |
| NCT02113241 | COMPLETED | Metabolic Syndrome X |
University of Guadalajara |
2014-04 | PHASE2; PHASE3 |
| NCT02157298 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2014-06 | PHASE4 |
| NCT02223065 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2014-09 | PHASE1 |
| NCT01525238 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2012-07-01 | PHASE1 |
| NCT01646320 | COMPLETED | Type 2 Diabetes |
AstraZeneca |
2012-09 | PHASE3 |
| NCT01619059 | COMPLETED | Type 2 Diabetes |
AstraZeneca |
2012-06 | PHASE3 |
| NCT02060201 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2014-02 | PHASE1 |
| NCT01877889 | COMPLETED | Healthy |
Janssen-Cilag International NV |
2013-07 | PHASE1 |
| NCT01606007 | COMPLETED | Type 2 Diabetes |
AstraZeneca |
2012-07 | PHASE3 |
| NCT01095666 | COMPLETED | Type 2 Diabetes |
AstraZeneca |
2010-06 | PHASE3 |
| NCT01195662 | COMPLETED | Type 2 Diabetes |
AstraZeneca |
2010-10 | PHASE3 |
| NCT01137474 | COMPLETED | Type 2 Diabetes |
AstraZeneca |
2010-07 | PHASE3 |
| NCT01662999 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2012-08 | PHASE1 |
| NCT01498185 | COMPLETED | Type 1 Diabetes Mellitus |
AstraZeneca |
2012-02 | PHASE2 |
| NCT01294423 | COMPLETED | Type 2 Diabetes; High Blood Sugar |
AstraZeneca |
2011-02 | PHASE3 |
| NCT01217892 | COMPLETED | Type 2 Diabetes |
AstraZeneca |
2010-11 | PHASE3 |
| NCT01042977 | COMPLETED | Type 2 Diabetes Mellitus; Cardiovascular Disease; Inadequate Glycaemic Control |
AstraZeneca |
2010-03 | PHASE3 |
| NCT00984867 | COMPLETED | Type 2 Diabetes |
AstraZeneca |
2009-10 | PHASE3 |
| NCT01165268 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2010-08 | PHASE1 |
| NCT00976495 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2009-10 | PHASE2 |
| NCT01156246 | COMPLETED | Healthy |
AstraZeneca |
2010-06 | PHASE1 |
| NCT00831779 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2009-04 | PHASE2 |
| NCT01135446 | COMPLETED | Type 2 Diabetes |
AstraZeneca |
2010-05 | PHASE1 |
| NCT00859898 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2009-04 | PHASE3 |
| NCT01055691 | COMPLETED | Healthy Volunteers |
AstraZeneca |
2010-01 | PHASE1 |
| NCT01068756 | TERMINATED | Type 2 Diabetes Mellitus |
AstraZeneca |
2010-03 | PHASE1 |
| NCT01072578 | COMPLETED | Healthy Volunteers |
AstraZeneca |
2010-02 | PHASE1 |
| NCT01055652 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2010-01 | PHASE1 |
| NCT00683878 | COMPLETED | Type 2 Diabetes |
AstraZeneca |
2008-07 | PHASE3 |
| NCT00736879 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2008-09-22 | PHASE3 |
| NCT00660907 | COMPLETED | Type 2 Diabetes |
AstraZeneca |
2008-03 | PHASE3 |
| NCT00663260 | COMPLETED | Diabetes Mellitus, Type 2 |
AstraZeneca |
2008-06 | PHASE2; PHASE3 |
| NCT01002807 | COMPLETED | Type 2 Diabetes Mellitus (T2DM) |
AstraZeneca |
2009-11 | PHASE1 |
| NCT00680745 | COMPLETED | Type 2 Diabetes |
AstraZeneca |
2008-04 | PHASE3 |
| NCT00930865 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2009-07 | PHASE1 |
| NCT00908271 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2009-07 | PHASE1 |
| NCT00904176 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2009-06 | PHASE1 |
| NCT00643851 | COMPLETED | Type 2 Diabetes |
AstraZeneca |
2008-06 | PHASE3 |
| NCT00726505 | TERMINATED | Diabetes, NOS |
AstraZeneca |
2009-06 | PHASE1 |
| NCT00842556 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2009-03 | PHASE1 |
| NCT00673231 | COMPLETED | Type 2 Diabetes |
AstraZeneca |
2008-04 | PHASE3 |
| NCT00839683 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2009-02 | PHASE1 |
| NCT00528372 | COMPLETED | Type 2 Diabetes |
AstraZeneca |
2007-09 | PHASE3 |
| NCT00528879 | COMPLETED | Type 2 Diabetes |
AstraZeneca |
2007-09 | PHASE3 |
| NCT00554450 | COMPLETED | Diabetes Mellitus, Type 2 |
AstraZeneca |
2006-03 | PHASE1 |
| NCT00538174 | COMPLETED | Diabetes Mellitus, Type 2 |
AstraZeneca |
2007-11 | PHASE1 |
| NCT00546741 | COMPLETED | Healthy Male and Female Subjects |
AstraZeneca |
2007-11 | PHASE1 |
| NCT00263276 | COMPLETED | Type 2 Diabetes |
AstraZeneca |
2005-12 | PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-03-18)
Check the
Dapagliflozin (BMS-512148)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Dapagliflozin (BMS-512148) Mechanism of Action: SGLT2 Inhibition in Renal Proximal Tubule Epithelial Cells Research
- Dapagliflozin (BMS-512148): Selectivity & Specificity
- Dapagliflozin (BMS-512148) Working Concentration | Cell Culture | Treatment
- Dapagliflozin (BMS-512148) Solubility in DMSO
- Dapagliflozin (BMS-512148) Storage
- Dapagliflozin (BMS-512148) Stability
- Dapagliflozin (BMS-512148) Combination Database
- Dapagliflozin (BMS-512148) Molecular Weight
- Dapagliflozin (BMS-512148) SMILES
- Dapagliflozin (BMS-512148) CAS Number
- Dapagliflozin (BMS-512148) Chemical Structure (2D and 3D)
- Dapagliflozin (BMS-512148) IC50 for Cell-based and Cell-free Assays
- Dapagliflozin (BMS-512148) Sigma (SML2804)? Try a better option.
- Dapagliflozin (BMS-512148) MedChemExpress (HY-10450)? Try a better option.
- Dapagliflozin (BMS-512148) Cayman (11574)? Try a better option.
- Dapagliflozin (BMS-512148) APExBIO (A5854)? Try a better option.
- Dapagliflozin (BMS-512148) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.